Paired Vagus Nerve Stimulation in Mobilization of Patients With Prolonged Disorders of Consciousness
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Apr 9, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to help patients with prolonged disorders of consciousness (pDOC), which can happen after severe brain injuries. The trial aims to see if pairing a type of nerve stimulation called transauricular vagus nerve stimulation (taVNS) with robotic tilt table mobilization (RTTM) can improve recovery for these patients. Currently, there aren’t many reliable treatments for pDOC, and this study hopes to find out if this combination can enhance patient outcomes safely and effectively.
To join the trial, participants must have been in a state of altered consciousness for more than three months due to a brain injury and be medically cleared to take part in physical therapy. The study will recruit 15 individuals who will undergo a 12-week rehabilitation program, which includes observing their usual care, participating in the new treatment, and then following up on their progress over time. It’s important to know that certain individuals, such as those who are medically unsafe for physical therapy or do not have a caregiver to help with consent, will not be eligible for the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a diagnosis of pDOC (includes coma, VS/UWS, MCS, MCS +, MCS-) as defined as disorder of consciousness (DOC) greater than 3 months post onset
- • Patients deemed medically safe to participate in physical therapy (PT) as evaluated by the study physicians.
- Exclusion Criteria:
- • Patients who have emerged from MCS (CRS-R score 6 on Motor Function scale and/or 2 on Communication Scale).
- • Patients medically unsafe for participation in PT as indicated by one of the study physicians (including but not limited to those receiving intravenous sedation, those with integumentary breakdown or known pressure injuries, those with cardiovascular or cerebrovascular conditions precluding initiation of physical therapy \[ie uncontrolled intracranial pressure, severe symptomatic orthostatic hypotension, etc.).
- • Patients with DOC less than 3 months post onset will also be excluded.
- • Patients who do not meet technical requirements of the RTTM device will be excluded
- • weighing greater than 135 kg
- • length of legs below 75 cm or above 100 cm,
- • fixed contractures of lower extremity including hip, knee, ankle, or foot).
- • Does not have an identified care partner or legally authorized representative to consent to participation
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Jenna Tosto-Mancuso
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported